Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis

Thrombosis and Haemostasis

Volumn 80, Issue 1, 1998, Pages 24-27

  Bouma, Bonno N ^a   Von Dem Borne, Peter A Kr ^a   Meijers, Joost C M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 9; FIBRIN; PROTEIN C; THROMBIN;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 11 DEFICIENCY; FIBRIN CLOT; FIBRINOLYSIS; HEMOPHILIA A; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS;

EID: 0031903490     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615132     Document Type: Short Survey

References (51)

1. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-2.
2. MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 1964; 202: 498-9.
3. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "Prima Ballerina. Thromb Haemost 1995; 74: 7-17.
4. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-8.
5. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinol 1991; 3: 465-8.
6. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-8.
7. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
8. Von dem Borne PAK, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72: 397-402.
9. von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
10. Cawthern KM, van't Veer C, Lock JB, Branda RF, Mann KG. Regulation of thrombin generation by tissue factor, factor Villa and factor XIa in a whole blood model. Blood 1996; 88: 520a (Abstr.).
11. Oliver JA, Monroe DM, Hoffman M, Roberts HR. Factor XI increases thrombin generation in a cell-based system in the absence of factor XII. Blood 1996; 88: 469a (Abstr.).
12. von dem Borne PAK, Mosnier LO, Tans G, Meijers JCM, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78: 834-9.
13. Osterud B, Rapaport S. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
14. Marlar RA, Kleiss AJ, Griffin JH. An alternative pathway of human blood coagulation. Blood 1982; 60: 1353-8.
15. Broze GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
16. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3422-45.
17. Ichinose A. The physiology and biochemistry of factor XIII. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Edinburgh: Churchill Livingstone 1994; pp 531-46.
18. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-90.
19. Gurewich V, Pannell R. Inactivation of single-chain urokinase (Pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69: 769-72.
20. Lijnen HR, van Hoef B, Collen D. Activation with plasmin of two-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment of thrombin. Eur J Bioch 1987; 169: 359-64.
21. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
22. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
23. Hendriks D, Scharpe S, Van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
24. Wang W, Hendriks D, Scharpe S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
25. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
26. von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a TAFI (thrombin activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
27. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity - a role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
28. Greenberg CS, Miraglia CC, Rickles FR, Shuman MA. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. J Clin Invest 1985; 75: 1463-70.
29. Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Abbink JJ, Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE. Quantification of plasma factor XII-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 1988; 72: 1841-8.
30. Pixley RA, dela Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Path 1992; 140: 897-906.
31. Van der Linden PWG, Hack CE, Eerenberg AJM, Struyvenberg A, van der Zwan JK. Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood 1993; 82: 1732-9.
32. Abbink JJ, Kamp AM, Nuijens JH, Eerenberg AJM, Swaak AJF, Hack CE. Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints. Ann Rheum Dis 1992; 51:123-8.
33. Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984; 73: 1249-53.
34. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15.
35. Bajzar L, Nesheim M, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996; 88: 2093-100.
36. De Fouw NJ, Haverkate F, Bertina RM. Protein C and fibrinolysis: a link between coagulation and fibrinolysis. Adv Exp Med Biol 1990; 281: 235-43.
37. Bajzar L, Nesheim ME. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993; 268: 8608-16.
38. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 1218-23.
39. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
40. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
41. Griffin JH. Blood coagulation - the thrombin paradox. Nature 1995; 378: 337-8.
42. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Anti-thrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-12.
43. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
44. Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB. Rosenberg RD. Factor IXa-factor Villa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79: 2039-47.
45. Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
46. Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
47. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
48. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 1984; 58: 741-53.
49. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Path 1989; 134: 1087-97.
50. Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PBA, Coles MD, Bloom AL, Kaufman JM, Beck P, Hanan CM, Biggs R. Epsilon-amino-caproic acid therapy for dental extractions in haemophilia and christmas disease: a double blind controlled trial. Br J Haematol 1971; 20: 463-75.
51. Minnema MC, Friederich PW, Levi M, von dem Borne PAK, Mosnier LO, Meijers JCM, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as antifibrinolytic factor. J Clin Invest 1998; 101: 10-4.